IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.

ABSTRACT:

Background

IBI362 (LY3305677) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes. The aim of this randomised, placebo-controlled, multiple ascending dose phase 1b study was to evaluate the safety, tolerability, pharmacokinetics and efficacy of IBI362 in Chinese adults with overweight or obesity.

Methods

This study enrolled adults with overweight (body mass index [BMI]≥24 kg/m²) accompanied by hyperphagia and/or at least one comorbidity or obesity (BMI≥28 kg/m²) from six study centres in China. Eligible participants were randomised 2:1 to receive once-weekly subcutaneous injection of IBI362 or placebo in each of the three ascending dose cohorts for 12 weeks wi

SUBMITTER: Ji L 

PROVIDER: S-EPMC8374649 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature